Beijing Second Pharmaceutical Co. was granted FDA approval for US use of Amlodipine Besylate, a long-acting calcium channel blocker that is prescribed for hypertension and angina. The drug is a generic version of Pfizer’s Norvasc®. According to the company, the approval is the first time the FDA has approved an oral, solid-dose product from a China-owned pharma. BSPC will market the product through a US-based distribution partner. More details....

Stock Symbol: (NYSE: PFE)     Share this with colleagues: